<DOC>
	<DOCNO>NCT02824432</DOCNO>
	<brief_summary>The purpose study explore effect omega-3-acid ethyl ester ( TAK-085 ) vascular endothelial function administer 8 week , measure FMD , patient hyperlipidemia .</brief_summary>
	<brief_title>Exploratory Study Effect Omega-3-acid Ethyl Esters ( TAK-085 ) Vascular Endothelial Function Patients With Hyperlipidemia Flow Mediated Dilation</brief_title>
	<detailed_description>This multicenter , collaborative , randomize , open-label study design explore effect administration omega-3-acid ethyl ester ( TAK-085 ) [ 2 g ( 2 g PO QD ) 4 g ( 2 g PO BID ) 8 week ] vascular endothelial function , measure flow-mediated dilation ( FMD ) , patient receive hydroxymethylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor concurrent hypertriglyceridemia ( hereinafter refer TG ) . Considering potential bias factor affect FMD treatment group , stratify allocation perform fasting TG level factor .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Participants diagnosis hyperlipidemia receive instruction lifestyle improvement 2 . Participants fast triglyceride ( TG ) level 150 499 mg/dL Visit 1 informed consent ( Day 29 Day 1 start study drug administration ) 3 . Participants receive stable dose HMGCoA reductase inhibitor therapy continuously least 4 week inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) 4 . Male postmenopausal female participant 5 . Participants , opinion principal investigator investigator , capable understanding content clinical research comply research protocol requirement . 6 . Participants provide write informed consent prior conduction clinical research procedures 7 . Participants age ≥20 year time inform consent Visit 1 ( Day 28 Day 0 start study drug administration ) 1 . Participants history revascularization coronary artery disease ( definitive diagnosis myocardial infarction , angina ) within 24 week inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) 2 . Participants undergo aortic aneurysmectomy within 24 week prior inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) concurrent aortic aneurysm 3 . Participants clinically significant hemorrhagic disorder ( e.g. , hemophilia , capillary fragility , gastrointestinal ulcer , urinary tract hemorrhage , hemoptysis , vitreous hemorrhage ) within 24 week prior inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) concurrently disorder 4 . Participant fast FMD level 0 % measure start study drug administration Visit 2 ( Day 15 Day 1 start study drug administration ) 5 . Participants type dosage HMGCoA reductase inhibitor , antidiabetic drug antihypertensive drug change within 4 week prior inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) 6 . Participants start anti dyslipidemic agent within 4 week prior inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) 7 . Participants require change dose dyslipidemia therapeutic , antidiabetic , antihypertensive drug period inform consent Visit 1 ( Day 29 Day 1 start study drug administration ) start study drug administration Visit 2 ( Day 15 Day 1 start study drug administration ) 8 . Participants severe hepatic dysfunction 9 . Participants severe renal dysfunction ( indicator , CKD category ≥G3b , equivalent A3 ) 10 . Participants diagnose pancreatitis 11 . Participants diagnose lipoprotein lipase deficiency , apoprotein CII deficiency , familial hypercholesterolemia , familial combine hyperlipidemia , familial type III hyperlipidemia 12 . Participants concurrent Cushing 's syndrome , uremia , systemic lupus erythematosus ( SLE ) , serum dysproteinemia , hypothyroidism 13 . Participants symptomatic Peripheral Arterial Disease ( PAD ) 14 . Participants concurrent hypertension grade II high Note 1 ) Note 1 : Participants systolic blood pressure ≥160 mm Hg diastolic BP ≥100 mm Hg regardless treatment antihypertensive drug 15 . Participants habitual drinker drink average 100 mL per day ( express term quantity alcohol ) participant , history drug abuse addiction Note 2 ) 16 . Participants history hypersensitivity allergy omega3acid ethyl ester 17 . Participants smoke 18 . Participants participate clinical study 19 . Participants determine ineligible subject study principal investigator investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>